Poly-L-lysine hydrobromide (MW 150000-300000)
(Synonyms: 多聚-L-赖氨酸氢溴酸盐) 目录号 : GC19602
Poly-L-lysine hydrobromide (MW 150000-300000)是一种高分子量、带正电的合成多肽,常用于增强细胞对培养表面的黏附,具有良好的水溶性和生物相容性,是原代神经元、上皮细胞和干细胞培养中的重要工具试剂。
Cas No.:25988-63-0
Sample solution is provided at 25 µL, 10mM.
Poly-L-lysine hydrobromide (MW 150000-300000) is a high-molecular-weight, positively charged synthetic polypeptide widely used to enhance cell adhesion to culture surfaces. Poly-L-lysine hydrobromide exhibits excellent water solubility and biocompatibility and serves as an essential reagent for the culture of primary neurons, epithelial cells, and stem cells[1-2]. When coated onto substrates, Poly-L-lysine hydrobromide forms a stable, uniform layer that resists detachment during long-term culture[3], and Poly-L-lysine hydrobromide is also employed as a drug-delivery vehicle[4].
In vitro, Poly-L-lysine hydrobromide (20μg/mL) applied to HeLa cells for 30min–2h significantly inhibits tumor-cell DNA, RNA, and protein synthesis, alters membrane permeability, induces leakage of intracellular small molecules, and causes cell rounding, granulation, and lysis[5]. Treatment of Jurkat T-cells, THLE-3 hepatocyte-like cells, and human umbilical vein endothelial cells (HUVEC) with Poly-L-lysine hydrobromide(10–30μg/ml) for 24h markedly induces apoptosis, as evidenced by mitochondrial membrane potential loss, cytochrome c release, and activation of caspase-9 and caspase-3.[6].
In vivo, Poly-L-lysine hydrobromide (50mg/kg/day; i.v.) administered to C57BL/6 mice bearing subcutaneous B16F10 melanoma on days 1 and 2 post-inoculation markedly suppresses tumor neovascularization, induces widespread tumor-cell apoptosis/necrosis, and delays solid-tumor growth[7]. A single intraluminal insertion of a 5-0 monofilament nylon suture coated with 0.1%w/v Poly-L-lysine hydrobromide into the internal carotid artery of C57BL/6 mice produces 30–180min middle-cerebral-artery occlusion followed by 24h reperfusion, resulting in 100% consistent infarcts in expected ipsilateral regions (striatum, thalamus, hippocampus, frontoparietal cortex) and time-dependent neurological deficits[8].
References:
[1] Olivera-Ardid S, Bello-Gil D, Tuzikov A et al, et al. Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases. Front Immunol. 2022 Mar 31;13:873019.
[2] Hatcher JM, Zwirek M, Sarhan AR, et al. Development of a highly potent and selective degrader of LRRK2. Bioorg Med Chem Lett. 2023 Oct 1;94:129449.
[3] Tengberg JF, Russo F, Benned-Jensen T, et al. LRRK2 and RAB8A regulate cell death after lysosomal damage in macrophages through cholesterol-related pathways. Neurobiol Dis. 2024 Nov;202:106728.
[4] Harsiddharay RK, Gupta A, Singh PK, et al. Poly-L-lysine Coated Oral Nanoemulsion for Combined Delivery of Insulin and C-Peptide. J Pharm Sci. 2022 Dec;111(12):3352-3361.
[5] Arnold LJ Jr, Dagan A, Gutheil J, et al. Antineoplastic activity of poly(L-lysine) with some ascites tumor cells. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3246-50.
[6] Symonds P, Murray JC, Hunter AC, et al. Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. FEBS Lett. 2005 Nov 7;579(27):6191-8.
[7] Al-Jamal KT, Al-Jamal WT, Akerman S, et al. Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):3966-71.
[8] Belayev L, Busto R, Zhao W, et al. Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. Brain Res. 1999 Jul 3;833(2):181-90.
Poly-L-lysine hydrobromide (MW 150000-300000)是一种高分子量、带正电的合成多肽,常用于增强细胞对培养表面的黏附,具有良好的水溶性和生物相容性,是原代神经元、上皮细胞和干细胞培养中的重要工具试剂[1-2]。Poly-L-lysine hydrobromide可在培养表面形成稳定、均一的包被层,使细胞在长期培养的过程中不易脱落[3],Poly-L-lysine hydrobromide还常被当成递送药物的载体[4]。
在体外,Poly-L-lysine hydrobromide(20μg/mL)处理作用于HeLa细胞30min–2h,可显著抑制肿瘤细胞DNA、RNA及蛋白合成,诱导膜通透性改变及胞内小分子外漏,并导致细胞形态变圆、颗粒化甚至溶解[5]。Poly-L-lysine hydrobromide(10–30μg/ml)处理Jurkat T细胞、THLE-3肝细胞样细胞及人脐静脉内皮细胞(HUVEC)24h,可显著诱导细胞凋亡,表现为线粒体膜电位下降、细胞色素c释放、caspase-9及caspase-3激活[6]。
在体内,Poly-L-lysine hydrobromide(50mg/kg/天)经尾静脉给予B16F10黑色素瘤皮下接种的C57BL/6小鼠,于后第1、2天各注射一次,显著抑制肿瘤新生血管形成,诱导肿瘤细胞广泛凋亡/坏死,并延迟实体瘤生长[7]。经Poly-L-lysine hydrobromide包被的5-0单丝尼龙线(0.1%w/v涂层)一次性经颈内动脉插入,阻断C57BL/6小鼠大脑中动脉30–180min,随后24h再灌注,可100%诱发同侧预期部位(纹状体、丘脑、海马及额顶皮质)的持续性梗死,并呈现时间依赖性神经功能缺损[8]。
Cell experiment [1]: | |
Cell lines | Jurkat T-cells, THLE-3 hepatocyte-like cells, and human umbilical vein endothelial cells (HUVEC) |
Preparation Method | Cells were seeded into 12- or 24-well plates at 1×10⁶ cells/ml and cultured in serum-free RPMI-1640. After 24h, fresh medium containing Poly-L-lysine hydrobromide (PLL) or PLL–DNA complexes was added. |
Reaction Conditions | 10–30μg/ml; 24h. |
Applications | Poly-L-lysine hydrobromide induced significant apoptosis, manifested by mitochondrial membrane potential loss, cytochrome c release, and activation of caspases-9 and -3. |
Animal experiment [2]: | |
Animal models | C57BL/6 mice (B16F10 melanoma) and SCID mice (P22 rat sarcoma). |
Preparation Method | Subcutaneous implantation of 1 × 10⁶ B16F10 cells or dorsal window-chamber implantation of P22 fragments; 24h later, mice received the first of two daily tail-vein administrations of Poly-L-lysine hydrobromide (50mg/kg) or PBS, followed by tissue harvest on day 10. |
Dosage form | 50mg/kg/day; i.v. |
Applications | Poly-L-lysine hydrobromide dendrimer significantly suppressed intratumoral vascularization, induced extensive tumor-cell apoptosis/necrosis, and delayed solid-tumor growth without systemic toxicity. |
References: |
Cas No. | 25988-63-0 | SDF | |
别名 | 多聚-L-赖氨酸氢溴酸盐 | ||
Canonical SMILES | CN[C@@H](CCCC[NH3+])C(C)=O.[n].[Br-].[n] | ||
分子式 | C8H19BrN2O | 分子量 | 150000-300000 |
溶解度 | H2O : 25 mg/mL (Need ultrasonic) | 储存条件 | 4°C, sealed storage, away from moisture and light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 0.0067 mL | 0.0333 mL | 0.0667 mL |
5 mM | 0.0013 mL | 0.0067 mL | 0.0133 mL |
10 mM | 0.0007 mL | 0.0033 mL | 0.0067 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch: